Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs
COVID-19 관리에서 표준 치료에 추가된 Tocilizumab: RCT의 메타 분석
Meta-Analysis
[키워드] 28-day mortality
95% CI
addition
Admission
adverse event
adverse events
Analysis
baseline
benefit
carried
clinical benefit
clinical benefits
Cochrane Library
control group
Controlled
controlled trials
coronavirus disease
Coronavirus disease 2019
COVID-19
defined
Direct
eligible
event
ICU
ICU admission
identify
include
initial
intensive care
intensive care unit
less
management
mechanical ventilation
Meta-analysis
Mortality
nine
Occurrence
Odds ratio
outcome
overall mortality
participant
Participants
Patient
performed
Primary outcome
progression
randomization
Randomized
RCT
RCTs
receiving
Science
Science Direct
secondary
Secondary outcomes
serious infection
serious infections
severe disease
Standard of care
statistically significant
Steroids
Subgroup analyses
survival
systematic review
Tocilizumab
use of steroid
[DOI] 10.23750/abm.v93i1.12208 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.23750/abm.v93i1.12208 PMC 바로가기 [Article Type] Meta-Analysis